Escalating cost of oral and injectable antihyperglycemic drugs; are newer medications worth their price? A perspective from India and other developing countries
- 4 February 2020
- journal article
- research article
- Published by Elsevier BV in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 14 (2), 167-169
- https://doi.org/10.1016/j.dsx.2020.01.012
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Socioeconomic factors relating to diabetes and its management in IndiaJournal of Diabetes, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetesEuropean Heart Journal, 2015
- Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answerDiabetes, Obesity and Metabolism, 2015
- Insulin Analogs—Is There a Compelling Case to Use Them? No!Diabetes Care, 2014
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusEmergencias, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised studyThe Lancet, 1999
- Oral Sulfonylurea Hypoglycemic Agents Prevent Ischemic Preconditioning in Human MyocardiumCirculation, 1997